Experienced in Zika Virus Disease

Dr. William J. Muller

Pediatric Infectious Disease | Infectious Disease
225 E Chicago Ave, Box 20, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Zika Virus Disease
225 E Chicago Ave, Box 20, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Muller is a Pediatric Infectious Disease specialist and an Infectious Disease provider in Chicago, Illinois. Dr. Muller is rated as an Experienced provider by MediFind in the treatment of Zika Virus Disease. His top areas of expertise are Neonatal Herpes, Severe Acute Respiratory Syndrome (SARS), Herpes Simplex Encephalitis, and COVID-19.

His clinical research consists of co-authoring 259 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Zika Virus Disease.

Specialties
Pediatric Infectious Disease
Infectious Disease
Licenses
Pediatric Infectious Diseases in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

225 E Chicago Ave, Box 20, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Enrollment Status: Recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections
An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Phase: Phase 1
Assessment of CMV-specific T Cell Responses by Flow Cytometry With Intracellular Cytokine Staining to Predict CMV Infection Risk in Pediatric Solid Organ Transplant Recipients
Assessment of CMV-specific T Cell Responses by Flow Cytometry With Intracellular Cytokine Staining to Predict CMV Infection Risk in Pediatric Solid Organ Transplant Recipients
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2024
Intervention Type: Other
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Enrollment Status: Completed
Publish Date: September 06, 2023
Intervention Type: Drug
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
View 6 Less Clinical Trials

259 Total Publications

Correction: Miniaturized scalable arrayed CRISPR screening in primary cells enables discovery at the single donor resolution.
Correction: Miniaturized scalable arrayed CRISPR screening in primary cells enables discovery at the single donor resolution.
Journal: Scientific reports
Published: September 30, 2025
Similar Doctors
Steven M. Wolinsky
Experienced in Zika Virus Disease
Dr. Steven M. Wolinsky
Infectious Disease
Experienced in Zika Virus Disease
Dr. Steven M. Wolinsky
Infectious Disease
645 N Michigan Ave Ste 900, 
Chicago, IL 
 (0.4 miles away)
708-923-4000
Experience:
47+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Wolinsky is an Infectious Disease provider in Chicago, Illinois. Dr. Wolinsky has been practicing medicine for over 47 years and is rated as an Advanced provider by MediFind in the treatment of Zika Virus Disease. His top areas of expertise are HIV/AIDS, Togaviridae Disease, Kaposi Sarcoma, and Zika Virus Disease.

Experienced in Zika Virus Disease
Dr. Maximo O. Brito
Infectious Disease
Experienced in Zika Virus Disease
Dr. Maximo O. Brito
Infectious Disease

The Board Of Trustees Of The University Of Illinois

1855 W Taylor St, Mc648, 
Chicago, IL 
 (3.3 miles away)
312-996-6590
Languages Spoken:
English, Spanish
See accepted insurances

Maximo Brito is an Infectious Disease provider in Chicago, Illinois. Dr. Brito is rated as an Advanced provider by MediFind in the treatment of Zika Virus Disease. His top areas of expertise are HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Muller's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile